Naloxone B. Braun (Naloxone Hydrochloride)

Naloxone competitively binds to μ, κ and δ opioid receptors, displacing opioid agonists from these sites. By blocking the receptors, it stops the opioids from exerting their depressant actions on the central nervous system, leading to a quick restoration of respiratory drive and alertness.

The dose of Naloxone B. Braun is determined by the prescribing clinician based on the severity of the overdose, the route of administration, and the patient’s response. Healthcare professionals adjust the amount and repeat dosing as needed to achieve adequate reversal.

Safety data for naloxone in pregnancy and lactation are limited. Because the drug does not cross the placenta in significant amounts and is not excreted in breast milk in harmful concentrations, it may be used when the benefits outweigh potential risks, but the decision should be made by a qualified healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Naloxone is the standard rapid‑acting opioid antagonist used in emergency settings, whereas agents like naltrexone have a longer duration but are not suitable for acute reversal. Compared with other naloxone brands, Naloxone B. Braun offers comparable potency, stability, and the same routes of administration.

Naloxone B. Braun should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and discard any vial that appears discolored or contains particles.

The product is supplied as a sterile injectable solution and can be given either intramuscularly or intravenously. Administration is performed by trained healthcare personnel, typically using a pre‑filled syringe or vial, with dosage adjusted according to clinical response.

The most serious risks include precipitating acute opioid withdrawal, severe hypertension, cardiac arrhythmias, seizures, and rare anaphylactic reactions. Patients should be closely monitored after administration, especially those with cardiovascular disease or a history of seizures.

Naloxone B. Braun is contraindicated in individuals with known hypersensitivity to naloxone or any component of the formulation. Caution is advised for patients receiving mixed agonist‑antagonist opioids, as effectiveness may be reduced.